Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis

Jun, Su Youn; Seok, Yang Ki; Kato, Tomoyasu; Chun, Da Som; Lee, Yoon Hee; Chong, Gun Oh; Cho, Young Lae; Hong, Dae Gy

doi:10.5468/ogs.2017.60.3.308

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The purpose of the 13th study was to examine the effectiveness of repeated intrapleural chemotherapy through a port system and report only the survival rate of the included patients 17 . Four studies reported no toxicity after the intrapleural chemotherapy 14,17,20,22 . In the complete cohort of 497 patients, 11 cases of myelosuppression and another 18 cases of other grade 3/4 toxicity were described.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis

et al. 2022

View full text Add to dashboard Cite

Breast and ovarian cancer account for over 30% of malignant pleural effusions (MPEs). Treatment of the metastatic disease requires control of the MPE. Even though primarily symptomatic, the treatment of the MPE can potentially affect the oncological course of the disease. The aim of this review is to analyze the effectiveness of intrathoracic chemotherapy in the treatment of MPE caused by breast and ovarian cancer. Methods: A systematic literature research was conducted up until May 2021. Studies published in English on patients undergoing either surgical or interventional intrapleural chemotherapy were included. Results: Thirteen studies with a total of 497 patients were included. Analysis was performed on 169 patients with MPE due to breast cancer and eight patients with MPE secondary to ovarian cancer. The pooled success rates of intrathoracic chemotherapy for controlling the MPE were 59.1% and 87.5%, respectively. A survival analysis was not possible with the available data. The overall toxicity of the treatment was low. Conclusions: Intrathoracic chemotherapy achieves symptomatic control of the MPE in 59.1% of patients with metastatic breast cancer and 87.5% of patients with metastatic ovarian cancer. This is inferior to other forms of surgical pleurodesis. Data from small case series and studies on intraperitoneal chemotherapy show promising results. However, formal oncological studies on the use of intrathoracic chemotherapy for metastatic breast or ovarian cancer are lacking. Further prospective pilot studies are needed to assess the therapeutic oncological effects of this treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 17 Four studies reported no toxicity after the intrapleural chemotherapy. 14 , 17 , 20 , 22 In the complete cohort of 497 patients, 11 cases of myelosuppression and another 18 cases of other grade 3/4 toxicity were described. One study established the levels of intrapleural toxicity of docetaxel.…”

Section: Resultsmentioning

confidence: 99%

Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…HIPEC with cytoreduction has demonstrated prolonged survival for pseudomyxoma peritonei (14). Isolated reports of debulking and HITHOC have been described with some success for both pseudomyxoma peritonei and ovarian carcinoma (15)(16)(17)(18)(19).…”

Section: Current Use Of Hithoc For Metastatic Diseasementioning

confidence: 99%

A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer

Song¹,

Flores²

2021

Ann Transl Med

View full text Add to dashboard Cite

The traditional treatment of stage IV lung cancer is predominantly supportive or palliative. No current standardized guidelines promote the use of hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of advanced lung cancer with pleural involvement. Several small studies have examined the safety and utilization of HITHOC for this population, though the data is extremely limited. A review of the literature is presented in accordance with the Narrative Review checklist. The MEDLINE electronic database was searched for articles published in English from January 1999 -August 2020 using relevant keywords such as "hyperthermic intrathoracic chemotherapy", "hyperthermic intrapleural chemotherapy" and "HITHOC". This was supplemented by review and hand search of the reference lists. While data suggest a potential though controversial role for HITHOC for certain intrathoracic tumors such as malignant pleural mesothelioma and thymoma, there is insufficient evidence to confidently promote a role for hyperthermic intrathoracic chemotherapy in the treatment of advanced lung cancers. Existing studies are small, nonrandomized, and prone to bias. Hyperthermic intrathoracic chemotherapy is not a standardized treatment for advanced lung cancer, and is characterized by potentially serious side effects with little clinical benefit. Recent developments in targeted therapy and immunotherapy are unlikely to leave room for the development of large randomized controlled trials.

show abstract

Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Patients with Intrapleural Dissemination of Peritoneal Surface Malignancies

et al. 2021

View full text Add to dashboard Cite

Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis

Cited by 4 publications

References 15 publications

Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis

Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis

A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer

Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Patients with Intrapleural Dissemination of Peritoneal Surface Malignancies

Contact Info

Product

Resources

About